U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Syringe, Piston - Product Code FMF
Cause
The firm believes that some of the syringes in the affected lots may not have received the intended sterilization dose.
Action
BD contacted their customers via phone and overnight mail letter . End users were notified by overnight mail with confirmation of delivery.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Syringe, Piston - Product Code FMF
Cause
The firm believes that some of the syringes in the affected lots may not have received the intended sterilization dose.
Action
BD contacted their customers via phone and overnight mail letter . End users were notified by overnight mail with confirmation of delivery.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Syringe, Piston - Product Code FMF
Cause
The firm believes that some of the syringes in the affected lots may not have received the intended sterilization dose.
Action
BD contacted their customers via phone and overnight mail letter . End users were notified by overnight mail with confirmation of delivery.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Syringe, Piston - Product Code FMF
Cause
The firm believes that some of the syringes in the affected lots may not have received the intended sterilization dose.
Action
BD contacted their customers via phone and overnight mail letter . End users were notified by overnight mail with confirmation of delivery.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Leaks and disconnection between the bifurcated y-site and the set tubing may occur and result in underdelivery of medication, blood loss, and a breach of the sterile fluid pathway.
Action
Baxter sent Urgent Product Recall letters dated 7/6/05 to their customers, to the attention of the Director of Materials Management, via first class mail on the same date. The accounts were informed of the complaints of leaks and disconnection between the bifurcated Y-site and the set tubing, resulting in the possible under delivery of medication, blood loss and a breach of the sterile fluid pathway. The accounts were instructed to examine their inventory for the affected lots of product, remove it from inventory and return it to Baxter for credit. Any questions were directed to the Center for One Baxter at 1-800-422-9837.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
infusion pump - Product Code MEA
Cause
During an infusion in the 'basal + pca' or 'pca only' modes, the syndeo pump may generate false service code 919 or service code 920, which will cause the pump to stop the infusion. also, while attempting to turn on the device by pressing the on/off key, the pump may not power up properly.
Action
Baxter sent Important Product Information letters dated 7/6/05 to all Syndeo Pump customers, to the attention of the Director of Nursing, via first class mail. The letter informed the accounts of the scenarios they may experience regarding Service Codes 919 and 920, and the pump not being able to power up properly. Mitigation for Service Codes 919 and 920 is to turn the pump off, then turn it on again, and reprogram the infusion. If the codes occur again, the accounts were instructed to take the pump out of service and contact Baxter Medication Delivery Services at 1-800-843-7867. Any questions were referred to the Center for One Baxter at 1-800-422-9837.
Baxter sent Product Withdrawal letters dated 12/11/09 to all Syndeo Pump customers, to the attention of the Director of Materials Management, with copies to the Director of Biomedical Engineering and the Director of Nursing. The letters informed the accounts that Baxter has stopped further development of the Syndeo pump platform, will pursue next generation PCA syringe pump technology and execute a controlled product withdrawal of the Syndeo pump over the next 12 months. Baxter sales representatives will contact the customers in the next few weeks to discuss options, including a Syndeo pump "buy back" plan, and to present alternative Baxter products to meet the customer's needs. The letters included a list of Syndeo pump serial numbers specific for each account, and requested the accounts to forward the letter to other facilities that they may have provided with Syndeo pumps. The accounts were requested to complete and fax back to Baxter the enclosed customer reply form, acknowledging receipt and understanding of the letter.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Pump, Infusion, Insulin - Product Code LZG
Cause
The adapter valve may not operate correctly, which may result in overdelivery of insulin in the first dose after the adapter has been changed.
Action
The firm began notifying family members of pediatric patients via phone on 7/15/05 and immediately began shipping a recall letter and 10 packs of replacement adapters to each pediatric user. Attending physicians were for these pediatric patients were notified the week of 7/18/05 via phone and follow-up letters were sent to these physicians. The firm is issuing a press release on 7/28/05. Only these replacement adapters are being sold by Disetronic to users of any age ordering new adapters.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Pump, Infusion - Product Code FRN
Cause
There is an overinfusion condition in the intermittent mode where the pump may continue to deliver at the higher dose rate instead of switching to the lower keep open rate once the first dose is completed.
Action
Baxter sent the 6/13/05 Urgent Device Correction letter to all Baxter 6060 and 6060E Infusion Pump customers to inform them of a software anomaly which allows the pump to overinfuse in the Intermittent mode of the 6060 pump if the following specific sequence of events occur: * the infusion is running in intermittent mode; * the pump is delivering at the Keep Open (KO) rate; * the pump is then powered off and on; * the clinician initiates new programming of the pump by selecting NO at the 'Resume KO Dose 1?' prompt and selecting YES at the 'Yes to Program' prompt; * the clinician powers the pump off and on again; * and the clinician selects YES at the 'Resume KO Dose 1?' prompt. Until the software upgrade is available, Baxter recommended that the accounts notify healthcare providers of the potential for an overinfusion condition in Intermittent mode if the above sequence is performed during an infusion, and to utilize the Lockout mode after programming the pump. Any questions were directed to Baxter''s Medication Delivery Services at 1-800-843-7867.
The letter also informed the accounts of two patient deaths due to medication delivery errors resulting from improper programming of the infusion parameters into the 6060 and 6060E pumps, and reports where the infusion parameters were modified by untrained individuals, which may result in overinfusion or underinfusion conditions. The letter stressed that programming of the pump must be performed only by trained clinicians, or healthcare providers trained and deemed competent by trained clinicians or under the direct supervision of trained clinicians; the Lockout mode feature of the pump should be used to prevent unauthorized changes to the pump programming; and the pump security codes, which disable the Lockout mode, must not be released to anyone other than trained healthcare professionals. A copy of the warning from the Operator''s Manual was included with the letter. Any questions were referred to the Center fo
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Leaks and disconnection between the bifurcated y-site and the set tubing may occur and result in underdelivery of medication, blood loss, and a breach of the sterile fluid pathway.
Action
Baxter sent Urgent Product Recall letters dated 7/6/05 to their customers, to the attention of the Director of Materials Management, via first class mail on the same date. The accounts were informed of the complaints of leaks and disconnection between the bifurcated Y-site and the set tubing, resulting in the possible under delivery of medication, blood loss and a breach of the sterile fluid pathway. The accounts were instructed to examine their inventory for the affected lots of product, remove it from inventory and return it to Baxter for credit. Any questions were directed to the Center for One Baxter at 1-800-422-9837.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Leaks and disconnection between the bifurcated y-site and the set tubing may occur and result in underdelivery of medication, blood loss, and a breach of the sterile fluid pathway.
Action
Baxter sent Urgent Product Recall letters dated 7/6/05 to their customers, to the attention of the Director of Materials Management, via first class mail on the same date. The accounts were informed of the complaints of leaks and disconnection between the bifurcated Y-site and the set tubing, resulting in the possible under delivery of medication, blood loss and a breach of the sterile fluid pathway. The accounts were instructed to examine their inventory for the affected lots of product, remove it from inventory and return it to Baxter for credit. Any questions were directed to the Center for One Baxter at 1-800-422-9837.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Leaks and disconnection between the bifurcated y-site and the set tubing may occur and result in underdelivery of medication, blood loss, and a breach of the sterile fluid pathway.
Action
Baxter sent Urgent Product Recall letters dated 7/6/05 to their customers, to the attention of the Director of Materials Management, via first class mail on the same date. The accounts were informed of the complaints of leaks and disconnection between the bifurcated Y-site and the set tubing, resulting in the possible under delivery of medication, blood loss and a breach of the sterile fluid pathway. The accounts were instructed to examine their inventory for the affected lots of product, remove it from inventory and return it to Baxter for credit. Any questions were directed to the Center for One Baxter at 1-800-422-9837.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Leaks and disconnection between the bifurcated y-site and the set tubing may occur and result in underdelivery of medication, blood loss, and a breach of the sterile fluid pathway.
Action
Baxter sent Urgent Product Recall letters dated 7/6/05 to their customers, to the attention of the Director of Materials Management, via first class mail on the same date. The accounts were informed of the complaints of leaks and disconnection between the bifurcated Y-site and the set tubing, resulting in the possible under delivery of medication, blood loss and a breach of the sterile fluid pathway. The accounts were instructed to examine their inventory for the affected lots of product, remove it from inventory and return it to Baxter for credit. Any questions were directed to the Center for One Baxter at 1-800-422-9837.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Pump, Infusion, Pca - Product Code MEA
Cause
The catheter tubing included in the kit may break during removal.
Action
Each consignee was notified of the recall via recall letter dated 2/7/06, which requested that they destroy the affected lots on site. International accounts were notified via email.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Catheter, Intravascular, Therapeutic, Long-Term Greater Than 30 Days - Product Code LJS
Cause
Guidewire protuding from tip of the catheter.
Action
The recalling firm issued a recall letter via fax to the distributors on 6/27/05. The letter informed the distributors of the problem and to notify any hospital accounts of the problem and the need to trim the catheter prior to implantation.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Medical Computers And Software - Product Code LNX
Cause
If an administrative user modifies any of the seven pre-defined monitoring parameters when they are attached to a medication in the drug file, a point of care end user will be unable to enter monitoring parameter results on the handheld.
Action
Urgent Device Correction recall letters dated 8/29/05 were sent to the direct accounts on the same date via first class mail. The letter describes the issue with the modification or creation of a Monitoring Parameter, and informed the accounts that modifying the Monitoring Parameters could result in a potential for a patient receiving an incorrect medication or an incorrect medication dosage. The accounts were advised that administrative end users should never modify the seven pre-defined Monitoring Parameters or create new Monitoring Parameters.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Drape, Surgical - Product Code KKX
Cause
Customer observed unsealed packages.
Action
The recalling firm called their customer and requested the customer to return un-sealed packages.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Pump, Infusion, Pca - Product Code MEA
Cause
The catheter tubing included in the kit may break during removal.
Action
Each consignee was notified of the recall via recall letter dated 2/7/06, which requested that they destroy the affected lots on site. International accounts were notified via email.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Syringe, Piston - Product Code FMF
Cause
Potential for the plunger to separate from the piston.
Action
CooperSurgical notified consignees by telephone and follow-up letter dated 11/3/05 via fax. Accounts are requested to discontinue use and return inventory.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Pump, Infusion - Product Code FRN
Cause
Possible shorting of some printed circuit boards could result in a possible interruption of therapy or cause the pump to fail the power-on self test.
Action
Baxter sent Urgent Device Correction letters dated 11/7/05 to the user accounts, advising them of the potential for the circuit boards in the 6060 pump to fail due to a problem that occurred in the supplier's manufacturing process. The letter included a list of 6060 pump serial numbers sent to the user that may contain an affected circuit board. To mitigate safety risks to the patient, Baxter advised customers to immediately discontinue use of the pump for therapies where interruption of the infusion could cause immediate patient harm. In addition, the pump is not to be used if it fails the Power-On Self Test. The accounts were instructed to contact Baxter Medication Delivery Services at 1-800-843-7867 for information regarding the return process for the affected 6060 pumps for correction.
Baxter sent follow-up letters dated 2/16/06 to the accounts, to the attention of the Director of Biomedical Engineering, informing them that Baxter has sufficient quantities of replacement circuit boards to begin the repairs. The accounts were requested to review the enclosed list of serial numbers for accuracy and telephone Baxter at 1-800-843-7867 to schedule the return of any 6060 Infusion Pump that requires replacement of the circuit board.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Stretcher, Wheeled - Product Code FPO
Cause
The firm received complaints of the stretchers folding. a fold is when the stretcher lowers on its own to either the next position, or any of the other seven postions of the stretcher.
Action
The firm went out to customers who had complained of a 'fold' and installed the kit on the stretcher that had experienced the fold and on all other PROflexx stretchers owned by the customer. These customers had received a recall letter, dated March 28, 2003. For customers that had not complained of the stretchers 'folding', the firm sent a letter dated June 24, 2003, to all distributors requesting the distributor provide the firm with a list of customers that had received the PROflex stretchers. Once the firm had a list of all customers, they sent them a letter offering them the kit as an enhancement that they could purchase to help reduce the possibility of false locking.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Stretcher, Wheeled - Product Code FPO
Cause
The firm received complaints of the stretchers folding. a fold is when the stretcher lowers on its own to either the next position, or any of the other seven postions of the stretcher.
Action
The firm went out to customers who had complained of a 'fold' and installed the kit on the stretcher that had experienced the fold and on all other PROflexx stretchers owned by the customer. These customers had received a recall letter, dated March 28, 2003. For customers that had not complained of the stretchers 'folding', the firm sent a letter dated June 24, 2003, to all distributors requesting the distributor provide the firm with a list of customers that had received the PROflex stretchers. Once the firm had a list of all customers, they sent them a letter offering them the kit as an enhancement that they could purchase to help reduce the possibility of false locking.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Pump, Infusion - Product Code FRN
Cause
Failures within the pca profile as well as incidents resulting in interruptions of therapy in various profiles.
Action
Baxter sent recall letters dated 11/14/05 to all of their 6060 pump customers on the same date via DHL overnight delivery. The accounts were informed of the reports of failures within the PCA profile and interruptions of therapy in various profiles. Due to the obsolescence of certain critical components, Baxter is conducting a controlled removal of all 6060 pumps from the market. Baxter will coordinate with customers individually to ensure a smooth transition to a substitute device. Baxter provided interim instructions to discontinue use of the PCA profile to avoid over infusion or non-delivery conditions, and to discontinue the use of the pump for therapies where interruption of the infusion could cause immediate patient harm.
Baxter representatives telephoned each account within 48 hours of the letter, and visited them within a week to help the customers transition to other infusion pumps. A press release issued on 11/15/05.
Baxter sent a follow-up recall letter to the accounts on 6/20/06, informing them that service repairs for the 6060 Infusion Pump will cease after 12/31/06, and compensation requests cannot be processed for pumps received after 12/31/06. Production of sets for the 6060 will cease on 10/1/06, and will not be available after 12/31/06. The accounts were requested to complete and fax back to Baxter the enclosed reply form, indicating the current inventory of 6060 pumps remaining at the facility.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
ICU Medical, Inc. acquired from Pfizer in early 2017, Hospira Infusion Systems, the portion of Hospira dedicated to develop infusion pumps.
Notes supplémentaires dans les données
Pump, Infusion, Pca - Product Code MEA
Cause
Incorrect values for dosage, dose limit, concentration or rate of delivery may display on screen.
Action
Field corrections initiated November 2, 2005. The firm has sent notification letters to consignees via Federal Express.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Lift, Patient, Non-Ac-Powered - Product Code FSA
Cause
Incorrect length leg pin bolts may cause patient lift failures.
Action
Liko Inc. initiated the recall to Distributors of the Recall on 11/14/05 via UPS. Direct customers will be notified by letter on /about 12/1/05.
U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Notes supplémentaires dans les données
Lift, Patient, Non-Ac-Powered - Product Code FSA
Cause
Incorrect length leg pin bolts may cause patient lift failures.
Action
Liko Inc. initiated the recall to Distributors of the Recall on 11/14/05 via UPS. Direct customers will be notified by letter on /about 12/1/05.